Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | CASP3 | P42574 | 2/20 | 0.63 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29851236 | 1.00 | KDR (0.71) | KDRMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL10994584 | 0.85 | KDR (0.58) | KDRMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL29903003 | 0.85 | HSP90AA1 (0.57) | KDRMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL1753903 | 0.84 | TDP1 (0.79) | KDRMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL14851783 | 0.84 | TDP1 (0.69) | KDRMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL27599095 | 0.84 | TDP1 (0.67) | KDRMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL3909349 | 0.84 | TDP1 (0.67) | KDRMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL3549883 | 0.84 | CYP1A2 (0.71) | KDRMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL29918706 | 0.84 | TDP1 (0.71) | KDRMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL5053488 | 0.84 | TDP1 (0.71) | KDRMEN1KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3715346-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-2970107-B1 | PHOTOSWITCHABLE HDAC INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-15 | — | — | EP | claimed |
| EP-3606528-B1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2023-10-18 | — | — | EP | claimed |
| EP-3172213-B1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3092220-B1 | VITAMIN C PRODRUGS AND USES THEREOF | UNIV FLORIDA (US) | 2021-01-20 | — | — | EP | claimed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | claimed |
| EP-2016044-B1 | PENTACYCLINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | HARVARD COLLEGE (US) | 2020-06-10 | — | — | EP | claimed |
| EP-3209648-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2020-03-11 | — | — | EP | claimed |
| EP-2550285-B1 | TRIOXACARCINS AND USES THEREOF | HARVARD COLLEGE (US) | 2017-07-19 | — | — | EP | claimed |
| EP-1833817-B1 | SYNTHESIS OF CCR5 RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2010-10-13 | — | — | EP | claimed |
| EP-1641754-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R, 2S, 5S)-3- AZABICYCLO[ 3, 1, 0]HEXANE-2-CARBOXAMIDE, N- [3-AMINO -1-(CYCLOBUTYLMETHYL)-2, 3-DIOXOPROPYL] ]-3- [ (2S)- 2-[[[1, 1-DIMETHYLETHYL ]AMINO]CARBONYLA MINO ]-3, 3-DIMETHYL-1-OXOBUTYL] -6, 6-DIMETHYL | SCHERING CORP (US) | 2008-03-26 | — | — | EP | claimed |
| EP-1436284-B1 | SYNTHESIS OF 4- (Z)-(4-BROMOPHENYL)(ETHOXYIMINO)METHYL]-1'- 2,4-DIMETHYL-1-OXIDO-3-PYRIDINYL)CARBONYL]-4'METHYL-1,4'BIPIPERIDINE | SCHERING CORP (US) | 2005-08-03 | — | — | EP | claimed |
| CN-113226468-B | Substituted alkylphenols as HCN1 antagonists | 康奈尔大学 | 2025-03-25 | — | — | CN | disclosed |
| CN-114174281-B | Degradation agent for cyclin-dependent kinase 7 (CDK 7) and use thereof | 达纳-法伯癌症研究公司 | 2025-02-07 | — | — | CN | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| CN-118660883-A | Polycyclic compounds and methods thereof | 海湃泰克(北京)生物医药科技有限公司 | 2024-09-17 | — | — | CN | disclosed |
| EP-2061765-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | Cylene Pharmaceuticals, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| US-4579865-A | ANTIISCHEMIC, HYPOGLYCEMIC AGENTS | USV PHARMACEUTICAL CORP. (US) | 1986-04-01 | — | — | US | disclosed |
| US-4530931-A | 8-Quinoline carbanilates for the inhibition of lipolysis | USV PHARMACEUTICAL CORP. (US) | 1985-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | KDR 2603/4885MEN1 1162/4885KMT2A 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.